Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05490888 · ClinicalTrials.gov registry record · Phase 1
Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics
A Phase 1 study of Cirrhosis, Liver and Liver Fibrosis, sponsored by PharmaIN.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
- 9
- Study locations
NCT05490888 is a Phase 1 study of Cirrhosis, Liver and Liver Fibrosis that is actively recruiting participants, run by PharmaIN. The registered enrollment target is 74 participants, below the 240-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (69% lower). The trial reports 9 study locations across 7 states.
The verdict
NCT05490888, a Phase 1 study of Cirrhosis, Liver and Liver Fibrosis, is actively recruiting participants, sponsored by PharmaIN.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
- 9
- Study locations
Study Summary
This 2-part study will evaluate PHIN-214 given as a single one-time dose (Part 1) and in multiple doses (given as daily doses for 28-days) (in Part 2). Specifically, this study evaluates PHIN-214, to determine the safety, tolerability, and pharmacokinetic effects of PHIN-214, and to establish the maximum tolerated dose or optimal beneficial dose in patients with Child Pugh A and B Cirrhosis.
Conditions Studied
Interventions
- DRUG PHIN-214 Subcutaneous injection
Study Locations (9)
Texas
- Methodist Health System, Dallas Medical Center - Dallas
- VA North Texas Healthcare System - Dallas
- Texas Liver Institute - San Antonio
Arizona
- Arizona Liver Health - Chandler
California
- Southern California Research Center - Coronado
Louisiana
- Tandem Clinical Research - Marrero
Minnesota
- Mayo Clinic - Rochester
Ohio
- Cleveland Clinic - Cleveland
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2022-01-03 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05490888
The ClinicalTrials.gov registry entry for NCT05490888 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 240-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (69% lower). The listed sponsor is PharmaIN, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Cirrhosis, Liver appearing as the primary indexed condition, and to 1 intervention - of which PHIN-214 Subcutaneous injection is the first listed.
NCT05490888 reports 9 study locations spanning 7 distinct geographic areas - top geographies include Texas, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT05490888 about?
NCT05490888 is a clinical study titled "Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics". This 2-part study will evaluate PHIN-214 given as a single one-time dose (Part 1) and in multiple doses (given as daily doses for 28-days) (in Part 2). Specifically, this study evaluates PHIN-214, to determine the safety, tolerability, and pharmacokinetic effects of PHIN-214, and to establish the ma...
What is the current status of trial NCT05490888?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2022-01-03. Estimated completion is 2026-06-30.
What conditions does trial NCT05490888 study?
This clinical trial studies the following conditions: Cirrhosis, Liver, Liver Fibrosis, Ascites Hepatic.
What interventions are being tested in trial NCT05490888?
The interventions under investigation include: PHIN-214 Subcutaneous injection (DRUG).
Who is sponsoring clinical trial NCT05490888?
This trial is sponsored by PharmaIN, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05490888 being conducted?
This trial has 9 study locations across Arizona, California, Louisiana, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis, Liver
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial
RECRUITING · Phase 1
-
A Study of SIPLIZUMAB in AILD and LT Patients
RECRUITING · Phase 1
-
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
COMPLETED · Phase 1
-
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
RECRUITING · Phase 4
-
Measuring Patient Reported Needs in Outpatient Liver Disease Management
RECRUITING
-
Molecular Mechanism of Exercise in Cirrhosis
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.